Introduction
Mucolipidosis type IV (MLIV, OMIM #252650) is an autosomal recessive, lysosomal storage disorder (Bach et al., 1975; Bargal et al., 2000; Tellez-Nagel et al., 1976) . Typically, the disease clinically presents at 1-2 years of age and over time leads to severe and progressive intellectual disability, motor and speech deficits, progressive retinopathy leading to blindness, systemic pathologies, and a shortened lifespan (Amir et al., 1987; Schiffmann et al., 2014; Venugopal et al., 2007) . There is currently no corrective therapy or cure for MLIV. The prevalence of MLIV is relatively high in the Ashkenazi Jewish population with an estimated carrier frequency of 1:100, but can also occur in the general population (Altarescu et al., 2002; Bargal et al., 2001 Bargal et al., , 2000 Edelmann et al., 2002) . The disease results from mutations in the gene encoding mucolipin-1 (MCOLN1), a 65 kDa protein also known as TRPML1 that serves as a transmembrane transient receptor potential (TRP) channel found in the limiting membrane of late endosomes and lysosomes (Bach, 2005; Bargal et al., 2000; Ye et al., 2004) . MCOLN1 is localized to chromosome 19p13.2-13.3 with both major and minor MLIV-causing mutations identified in MCOLN1, as well as over 20 independent mutations (Bargal et al., 2001 (Bargal et al., , 2000 Slaugenhaupt et al., 1999; Sun et al., 2000; Venugopal et al., 2007; Wakabayashi et al., 2011) . These mutations range from causing reduced mRNA expression to yielding nonfunctional protein (Sun et al., 2000; Wakabayashi et al., 2011) . Mucolipin-1 is ubiquitously expressed with highest expression in the brain and kidney (Bach, 2005; Cheng et al., 2010) and its loss leads to systemic disease accompanied by severe neurological pathology.
The function of mucolipin-1 is not fully understood, but it is known that it serves a critical role in pH regulation and as a nonselective ion channel permeable to calcium, iron, and other cations (Bach, 2005;  Neurobiology of Disease 105 (2017) 257-270
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